These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26517361)

  • 21. Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis.
    Billeskov R; Grandal MV; Poulsen C; Christensen JP; Winther N; Vingsbo-Lundberg C; Hoang TT; van Deurs B; Song YH; Aagaard C; Andersen P; Dietrich J
    Eur J Immunol; 2010 May; 40(5):1342-54. PubMed ID: 20186878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the development of TB Vaccines.
    Zenteno-Cuevas R
    Curr Pharm Biotechnol; 2013; 14(11):940-6. PubMed ID: 24372249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of new tuberculosis vaccine in children.
    Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S
    Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of M. tuberculosis Immune Evasion as Challenges to TB Vaccine Design.
    Ernst JD
    Cell Host Microbe; 2018 Jul; 24(1):34-42. PubMed ID: 30001523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in tuberculosis vaccine strategies.
    Skeiky YA; Sadoff JC
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4⁺ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs.
    Commandeur S; van den Eeden SJ; Dijkman K; Clark SO; van Meijgaarden KE; Wilson L; Franken KL; Williams A; Christensen D; Ottenhoff TH; Geluk A
    Vaccine; 2014 Jun; 32(29):3580-8. PubMed ID: 24837764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and solutions for a rational vaccine design for TB-endemic regions.
    Gowthaman U; Mushtaq K; Tan AC; Rai PK; Jackson DC; Agrewala JN
    Crit Rev Microbiol; 2015; 41(3):389-98. PubMed ID: 24495096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy.
    Griffiths KL; Ahmed M; Das S; Gopal R; Horne W; Connell TD; Moynihan KD; Kolls JK; Irvine DJ; Artyomov MN; Rangel-Moreno J; Khader SA
    Nat Commun; 2016 Dec; 7():13894. PubMed ID: 28004802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
    McShane H; Pathan AA; Sander CR; Goonetilleke NP; Fletcher HA; Hill AV
    Tuberculosis (Edinb); 2005; 85(1-2):47-52. PubMed ID: 15687027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions.
    Gowthaman U; Rai PK; Khan N; Jackson DC; Agrewala JN
    Trends Mol Med; 2012 Oct; 18(10):607-14. PubMed ID: 22939171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel vaccine candidates against Mycobacterium tuberculosis.
    Khoshnood S; Heidary M; Haeili M; Drancourt M; Darban-Sarokhalil D; Nasiri MJ; Lohrasbi V
    Int J Biol Macromol; 2018 Dec; 120(Pt A):180-188. PubMed ID: 30098365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future vaccination strategies against tuberculosis: thinking outside the box.
    Kaufmann SH
    Immunity; 2010 Oct; 33(4):567-77. PubMed ID: 21029966
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Ryndak MB; Laal S
    Front Cell Infect Microbiol; 2019; 9():299. PubMed ID: 31497538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycobacterium tuberculosis infection and vaccine development.
    Tang J; Yam WC; Chen Z
    Tuberculosis (Edinb); 2016 May; 98():30-41. PubMed ID: 27156616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunology of tuberculosis: impact on the development of novel vaccines].
    Ulrichs T; Kaufmann SH
    Internist (Berl); 2003 Nov; 44(11):1374-84. PubMed ID: 14689073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice.
    Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Eum SY; Cho SN; Shin SJ
    PLoS One; 2015; 10(10):e0141577. PubMed ID: 26509812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New approaches to TB vaccination.
    Xing Z; Jeyanathan M; Smaill F
    Chest; 2014 Sep; 146(3):804-812. PubMed ID: 25180725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c).
    Romano M; Rindi L; Korf H; Bonanni D; Adnet PY; Jurion F; Garzelli C; Huygen K
    Vaccine; 2008 Nov; 26(48):6053-63. PubMed ID: 18822333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of clinical models for the evaluation of human TB vaccines.
    O'Shea MK; McShane H
    Hum Vaccin Immunother; 2016 May; 12(5):1177-87. PubMed ID: 26810964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary mucosal dendritic cells in T-cell activation: implications for TB therapy.
    McCormick S; Shaler CR; Xing Z
    Expert Rev Respir Med; 2011 Feb; 5(1):75-85. PubMed ID: 21348588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.